On the other hand, weak, sub-optimal, and chronic I-IFN signaling supports tumor progression and resistance to therapy by cancer cell-intrinsic effects (i.e. mediating cytoprotective activity, promoting epithelial-to-mesenchymal transition and stemness) and establishment of an immunologically exhausted TME [109]. The gene discussed is IFNA1; the disease is cancer.